Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Glaucoma Treatment Pipeline Review H2 2016

Thursday, October 20, 2016 0:04
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Glaucoma – Pipeline Review, H2 2016’, provides an overview of the Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/693295-glaucoma-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Glaucoma 
- The report reviews pipeline therapeutics for Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Glaucoma therapeutics and enlists all their major and minor projects 
- The report assesses Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Glaucoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Glaucoma 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693295-glaucoma-pipeline-review-h2-2016

Key points in table of content

Table of Contents 2 
Introduction 6 
Glaucoma Overview 7 
Therapeutics Development 8 
Glaucoma – Therapeutics under Development by Companies 10 
Glaucoma – Therapeutics under Investigation by Universities/Institutes 16 
Glaucoma – Pipeline Products Glance 17 
Glaucoma – Products under Development by Companies 21 
Glaucoma – Products under Investigation by Universities/Institutes 27 
Glaucoma – Companies Involved in Therapeutics Development 28 
Glaucoma – Therapeutics Assessment 87 
Drug Profiles 103 
Glaucoma – Dormant Projects 263 
Glaucoma – Discontinued Products 271 
Glaucoma – Product Development Milestones 273 
Appendix 284

List of Tables 
Number of Products under Development for Glaucoma, H2 2016 21 
Number of Products under Development for Glaucoma – Comparative Analysis, H2 2016 22 
Number of Products under Development by Companies, H2 2016 24 
Number of Products under Development by Companies, H2 2016 (Contd..1) 25 
Number of Products under Development by Companies, H2 2016 (Contd..2) 26 
Number of Products under Development by Companies, H2 2016 (Contd..3) 27 
Number of Products under Development by Companies, H2 2016 (Contd..4) 28 
Number of Products under Investigation by Universities/Institutes, H2 2016 29 
Comparative Analysis by Late Stage Development, H2 2016 30 
Comparative Analysis by Clinical Stage Development, H2 2016 31 
Comparative Analysis by Early Stage Development, H2 2016 32 
Comparative Analysis by Unknown Stage Development, H2 2016 33 
Products under Development by Companies, H2 2016 34 
Products under Development by Companies, H2 2016 (Contd..1) 35 
Products under Development by Companies, H2 2016 (Contd..2) 36 
Products under Development by Companies, H2 2016 (Contd..3) 37 
Products under Development by Companies, H2 2016 (Contd..4) 38 
Products under Development by Companies, H2 2016 (Contd..5) 39 
Products under Investigation by Universities/Institutes, H2 2016 40 
Glaucoma – Pipeline by AC Immune SA, H2 2016 41 
Glaucoma – Pipeline by Acadia Pharmaceuticals Inc., H2 2016 42 
Glaucoma – Pipeline by Advanced Refractive Technologies, Inc., H2 2016 43 
Glaucoma – Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 44 
Glaucoma – Pipeline by Allergan Plc, H2 2016 45 
Glaucoma – Pipeline by Altacor Limited, H2 2016 46 
Glaucoma – Pipeline by Amakem NV, H2 2016 47 
Glaucoma – Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 48 
Glaucoma – Pipeline by Amgen Inc., H2 2016 49 
Glaucoma – Pipeline by Astellas Pharma Inc., H2 2016 50 
Glaucoma – Pipeline by Bausch & Lomb Incorporated, H2 2016 51 
Glaucoma – Pipeline by BioAxone BioSciences, Inc., H2 2016 52 
Glaucoma – Pipeline by Bionure Farma, S.L., H2 2016 53 
Glaucoma – Pipeline by Coronis Partners Ltd., H2 2016 54 
Glaucoma – Pipeline by D. Western Therapeutics Institute, Inc., H2 2016 55 
Glaucoma – Pipeline by Dompe Farmaceutici S.p.A., H2 2016 56 
Glaucoma – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 57 
Glaucoma – Pipeline by Gilead Sciences, Inc., H2 2016 58 
Glaucoma – Pipeline by Glaukos Corporation, H2 2016 59 
Glaucoma – Pipeline by Graybug Vision Inc, H2 2016 60 
Glaucoma – Pipeline by Handok Inc., H2 2016 61 
Glaucoma – Pipeline by HitGen LTD, H2 2016 62 
Glaucoma – Pipeline by Icon Bioscience, Inc., H2 2016 63 
Glaucoma – Pipeline by ID Pharma Co., Ltd., H2 2016 64 
Glaucoma – Pipeline by InMed Pharmaceuticals Inc., H2 2016 65 
Glaucoma – Pipeline by Inotek Pharmaceuticals Corporation, H2 2016 66 
Glaucoma – Pipeline by InSite Vision Incorporated, H2 2016 67 
Glaucoma – Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 68 
Glaucoma – Pipeline by Isarna Therapeutics GmbH, H2 2016 69 
Glaucoma – Pipeline by Kala Pharmaceuticals, Inc., H2 2016 70 
Glaucoma – Pipeline by Kowa Company, Ltd., H2 2016 71 
Glaucoma – Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016 72 
Glaucoma – Pipeline by Laboratoires Thea S.A., H2 2016 73 
Glaucoma – Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016 74 
Glaucoma – Pipeline by Lee’s Pharmaceutical Holdings Limited, H2 2016 75 
Glaucoma – Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 76 
Glaucoma – Pipeline by Merck & Co., Inc., H2 2016 77 
Glaucoma – Pipeline by Nemus Bioscience, Inc., H2 2016 78 
Glaucoma – Pipeline by NicOx S.A., H2 2016 79 
Glaucoma – Pipeline by NoNO, Inc., H2 2016 80 
Glaucoma – Pipeline by Novaliq GmbH, H2 2016 81 
Glaucoma – Pipeline by Ocular Therapeutix, Inc., H2 2016 82 
Glaucoma – Pipeline by Oculis ehf, H2 2016 83 
Glaucoma – Pipeline by Ohr Pharmaceutical Inc., H2 2016 84 
Glaucoma – Pipeline by Otsuka Holdings Co., Ltd., H2 2016 85 
Glaucoma – Pipeline by Oxford BioMedica Plc, H2 2016 86 
Glaucoma – Pipeline by Profarma, H2 2016 87 
Glaucoma – Pipeline by pSivida Corp., H2 2016 88 
Glaucoma – Pipeline by Quark Pharmaceuticals, Inc., H2 2016 89 
Glaucoma – Pipeline by Quethera Limited, H2 2016 90 
Glaucoma – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 91 
Glaucoma – Pipeline by Sanofi, H2 2016 92 
Glaucoma – Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 93 
Glaucoma – Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016 94 
Glaucoma – Pipeline by Shire Plc, H2 2016 95 
Glaucoma – Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 96 
Glaucoma – Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 97 
Glaucoma – Pipeline by Sylentis S.A.U., H2 2016 98 
Glaucoma – Pipeline by ViSci Ltd., H2 2016 99 
Assessment by Monotherapy Products, H2 2016 100 
Assessment by Combination Products, H2 2016 101 
Number of Products by Stage and Target, H2 2016 103 
Number of Products by Stage and Mechanism of Action, H2 2016 108 
Number of Products by Stage and Route of Administration, H2 2016 113 
Number of Products by Stage and Molecule Type, H2 2016 115 
Glaucoma – Dormant Projects, H2 2016 276 
Glaucoma – Dormant Projects (Contd..1), H2 2016 277 
Glaucoma – Dormant Projects (Contd..2), H2 2016 278 
Glaucoma – Dormant Projects (Contd..3), H2 2016 279 
Glaucoma – Dormant Projects (Contd..4), H2 2016 280 
Glaucoma – Dormant Projects (Contd..5), H2 2016 281 
Glaucoma – Dormant Projects (Contd..6), H2 2016 282 
Glaucoma – Dormant Projects (Contd..7), H2 2016 283 
Glaucoma – Discontinued Products, H2 2016 284 
Glaucoma – Discontinued Products (Contd..1), H2 2016 285

List of Figures 
Number of Products under Development for Glaucoma, H2 2016 21 
Number of Products under Development for Glaucoma – Comparative Analysis, H2 2016 22 
Number of Products under Development by Companies, H2 2016 23 
Number of Products under Investigation by Universities/Institutes, H2 2016 29 
Comparative Analysis by Late Stage Development, H2 2016 30 
Comparative Analysis by Clinical Stage Development, H2 2016 31 
Comparative Analysis by Early Stage Products, H2 2016 32 
Comparative Analysis by Unknown Stage Development, H2 2016 33 
Assessment by Monotherapy Products, H2 2016 100 
Assessment by Combination Products, H2 2016 101 
Number of Products by Top 10 Targets, H2 2016 102 
Number of Products by Stage and Top 10 Targets, H2 2016 102 
Number of Products by Top 10 Mechanism of Actions, H2 2016 107 
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 107 
Number of Products by Top 10 Routes of Administration, H2 2016 112 
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 112 
Number of Products by Top 10 Molecule Types, H2 2016 114 
Number of Products by Stage and Top 10 Molecule Types, H2 2016 114

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693295

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.